ARB ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
66IgA腎症8

66. IgA腎症


臨床試験数 : 275 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02981212
(ClinicalTrials.gov)
June 201624/11/2016Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA NephropathyMulti-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA NephropathyIgA NephropathyDrug: Mycophenolate Mofetil;Drug: ACE inhibitor;Drug: Corticosteroid;Drug: ARBYonsei UniversityChong Kun Dang Pharmaceutical Corp.;Kyung Hee University Hospital at Gangdong;Kyungpook National University;Pusan National University Yangsan Hospital;Inje University;Seoul St. Mary's Hospital;Chonbuk National University HospitalRecruiting19 Years65 YearsBoth100Phase 4Korea, Republic of
2NCT02571842
(ClinicalTrials.gov)
January 20126/10/2015Rituximab in Recurrent IgA NephropathyA Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation PathologyRecurrent IgA NephropathyDrug: Intravenous Rituximab;Drug: ACEI/ARB and corticosteroidsChulalongkorn UniversityNULLRecruiting18 Years70 YearsBoth30Phase 4Thailand
3ChiCTR-TRC-09000338
2009-04-012009-02-23Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathyFull dose of RASS blockade versus steroids therapy in patients with IgA nephropathy IgA nephropathyGroup A:Full dose of RASS blockade (ACEI and ARB blocker);Group B:prednisone ;The First Affiliated Hospital of Zhejiang UniversityNULLCompleted1870MaleGroup A:60;Group B:60;China
4NCT00498368
(ClinicalTrials.gov)
February 20099/7/2007Rituximab in Progressive Immunoglobulin A (IgA) NephropathyA Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA NephropathyIgA NephropathyDrug: Intravenous Rituximab;Drug: ACE/ARB;Dietary Supplement: Omega-3 Fatty Acid Fish Oil SupplementMayo ClinicOhio State University;Stanford University;University of North Carolina, Chapel Hill;Columbia University;Genentech, Inc.;BiogenCompleted18 Years70 YearsAll34Phase 4United States
5NCT00554502
(ClinicalTrials.gov)
February 200829/10/2007Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA NephropathySupportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA NephropathyIgA NephropathyDrug: supportive therapy with: ACE-inhibitor / ARB / Statin;Drug: supportive and immunosuppressive therapyRWTH Aachen UniversityNULLCompleted18 Years70 YearsBoth148Phase 3Germany
6ChiCTR-TRC-06000004
2006-01-012006-09-14ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trialACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial primary IgA nephropathygroup 1:treated with ACEI/ARB( ARB therapy is subjected to patients with cough after use of ACEI) Inhibace (cilazapril): start at 1.25mg/day, increase the dose by 1.25mg/day/week to 2.5-5mg/day Cozaar (losartan): 25~50mg/day, increased to 50~100mg/day Last for one year;group 2:Oral prednisone for 6 mos 0.8mg/kg/day x 8 wks Tapered 0.2mg/kg/day/mo in combination with ACEI/ARB;The First Hospital, Peking UniversityNULLCompleted1665Bothgroup 1:78;group 2:78;China
7NCT00378443
(ClinicalTrials.gov)
January 200619/9/2006ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCTGlomerulonephritis, IGADrug: prednisone + Inhibace/Cozaar;Drug: Inhibace/CozaarPeking UniversityNULLActive, not recruiting16 Years65 YearsBothN/ANULL
8JPRN-C000000380
2003/04/0131/03/2006The renoprotective effects of ARB in patients with IgA nephropathy : multicenter,radomized trialThe renoprotective effects of ARB in patients with IgA nephropathy : multicenter,radomized trial - ARB and IgA nephropathy IgA nephropathyARB valsartan

ACE-I enalapril
ARB therapeutic society of IgA nephropathyNULLComplete: follow-up complete16years-old75years-oldMale and Female400Phase 4Japan